{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:20Z","timestamp":1786985420614,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bmc.2026.118642","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:44:03Z","timestamp":1774658643000},"page":"118642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The synthesis and biological evaluation of novel deuterated and non-deuterated aminobenzenesulfonamide derivatives as EGFR inhibitor"],"prefix":"10.1016","volume":"137","author":[{"given":"Puzhuang","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longcai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmc.2026.118642_bb0005","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(18)30488-1","article-title":"Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment","volume":"7","author":"Chen","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.bmc.2026.118642_bb0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jtho.2024.01.019","article-title":"The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification for lung cancer","volume":"19","author":"Fong","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.bmc.2026.118642_bb0015","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A Review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.bmc.2026.118642_bb0020","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2025.05.024","article-title":"Advances in lung cancer basic and translational research in 2025 \u2013 overview and perspectives focusing on NSCLC","volume":"20","author":"Mascaux","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmc.2026.118642_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2019.10.009","article-title":"Epidemiology of lung cancer and lung cancer screening programs in China and the United States","volume":"468","author":"Yang","year":"2020","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.bmc.2026.118642_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001492","article-title":"Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"10.1016\/j.bmc.2026.118642_bb0035","first-page":"387","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CAA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.bmc.2026.118642_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bkcs.11348","article-title":"Synthesis of 4-anilinoquinazoline-derivative dual kinase inhibitors targeting EGFR and VEGFR-2","volume":"39","author":"Bang","year":"2018","journal-title":"Bull Korean Chem Soc"},{"issue":"11","key":"10.1016\/j.bmc.2026.118642_bb0045","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bmc.2026.118642_bb0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2018","journal-title":"Drug Discov Today"},{"issue":"15_suppl","key":"10.1016\/j.bmc.2026.118642_bb0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9578","article-title":"Correlation of gefitinib and its metabolites with gefitinib induce rash in patients with non-small cell lung cancer (NSCLC)","volume":"38","author":"Guan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118642_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.bmc.2026.118642_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117241","article-title":"Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M\/L858R mutations and ALK rearrangement as anticancer agents","volume":"85","author":"Cao","year":"2023","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118642_bb0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14656566.2021.1888928","article-title":"An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update","volume":"22","author":"Cerbone","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.bmc.2026.118642_bb0075","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118642_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2020.09.023","article-title":"Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib","volume":"150","author":"Gu","year":"2020","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.bmc.2026.118642_bb0085","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1200\/JCO.2005.05.3785","article-title":"Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question","volume":"24","author":"Baselga","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118642_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70921","article-title":"Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bmc.2026.118642_bb0095","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFRL858R\/T790M and EGFRL858R\/T790M\/C797S resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118642_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106057","article-title":"Overcoming C797S mutation: the challenges and prospects of the fourth-generation EGFR-TKIs","volume":"128","author":"Zhao","year":"2022","journal-title":"Bioorg Chem"},{"issue":"13","key":"10.1016\/j.bmc.2026.118642_bb0105","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it?","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118642_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.bmc.2026.118642_bb0115","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-21-0835","article-title":"HJM-561, a potent, selective, and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations","volume":"21","author":"Du","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bmc.2026.118642_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400836","article-title":"The application of deuteration strategy in drug design","volume":"20","author":"Chen","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2026.118642_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107313","article-title":"The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance","volume":"146","author":"Liu","year":"2024","journal-title":"Bioorg Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118642_bb0130","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1039\/D0CS01496F","article-title":"C\u2013H deuteration of organic compounds and potential drug candidates","volume":"51","author":"Prakash","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2026.118642_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108467","article-title":"Synthesis and evaluation of novel amino pyrimidine derivatives containing sulfonamide and their application as EGFR inhibitors","volume":"160","author":"Yao","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118642_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104246","article-title":"The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: a scoping review","volume":"194","author":"Belloni","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118642_bb0145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/acs.jmedchem.0c02005","article-title":"Discovery of dosimertinib, a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung Cancer","volume":"64","author":"Meng","year":"2021","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118642_bb0150","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/1759-7714.13587","article-title":"Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats","volume":"11","author":"Wu","year":"2020","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.bmc.2026.118642_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/14737140.2016.1162103","article-title":"The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer","volume":"16","author":"Gao","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.bmc.2026.118642_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ml300327z","article-title":"Structure-based approach for the discovery of pyrrolo [3,2-d] pyrimidine-based EGFR T790M\/L858R mutant inhibitors","volume":"4","author":"Sogabe","year":"2013","journal-title":"ACS Med Chem Lett"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:58:13Z","timestamp":1779425893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S0968089626000982"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118642","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The synthesis and biological evaluation of novel deuterated and non-deuterated aminobenzenesulfonamide derivatives as EGFR inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118642"}}